Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/121584
Título: Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
Autores/as: Bouzas, Cristina
Pastor, Rosario
Garcia, Silvia
Monserrat-Mesquida, Margalida
Martínez-González, Miguel Ángel
Salas-Salvadó, Jordi
Corella, Dolores
Goday, Albert
Martínez, J. Alfredo
Alonso-Gómez, Ángel M.
Fernández-Barceló, Olga
Vioque, Jesús
Romaguera, Dora
Lopez-Miranda, José
Estruch, Ramón
Tinahones, Francisco J.
Lapetra, José
Serra Majem, Luis 
Riquelme-Gallego, Blanca
Martín-Sánchez, Vicente
Pintó, Xavier
Delgado-Rodriguez, Miguel
Matía, Pilar
Vidal, Josep
Cardenas-Salas, Jersy Jair
Daimiel, Lidia
Ros, Emilio
Toledo, Estefanía
Manzanares, Josep M.
Gonzalez-Monge, Inmaculada
Muñoz, Miguel Ángel
Martinez-Urbistondo, Diego
Tojal-Sierra, Lucas
Muñoz-Bravo, Carlos
Miralles-Gisbert, Salvador
Martin, Marian
García-Ríos, Antonio
Castro-Barquero, Sara
Fernández-García, José Carlos
Santos-Lozano, José Manuel
Basterra-Gortari, F. Javier
Gutiérrez-Carrasquilla, Liliana
Guillem-Saiz, Patricia
Satorres, Alba
Abete, Itziar
Sorto-Sanchez, Carolina
Díez-Espino, Javier
Babio, Nancy
Fitó, Montse
Tur, Josep A.
Clasificación UNESCO: 32 Ciencias médicas
3209 Farmacología
Palabras clave: 4-Dipeptidyl Peptidase Inhibitors
Dpp-4I
Glp-1Ra
Glucagon-Like Peptide 1 Agonists
Metabolic Syndrome
Fecha de publicación: 2023
Proyectos: Efecto de la dieta mediterránea hopocalórica y promoción de la actividad física en prevención primaria cardiovascular.Estudio piloto sobre marcadores intermedios. 
Publicación seriada: Biomedicine and Pharmacotherapy 
Resumen: Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires. Results: MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: −1.7 mg/dL(± 13.5); ∆ metformin: − 2.5(± 23.9) mg/dL; ∆ DPP-4I: − 4.5(± 42.6); mg/dL ∆ GLP-1RA: − 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: − 0.1(± 0.7) %; ∆ DPP-4I: − 0.1(± 1.0) %; ∆ GLP-1RA: − 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: −0.8(± 1.6) kg/m2; ∆ metformin: − 0.8(± 1.5) kg/m2; ∆ DPP-4I: − 0.6(± 1.3) kg/m2; ∆ GLP-1RA: − 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: −2.8(± 5.2) cm; ∆ metformin: − 2.6(± 15.2) cm; ∆ DPP-4I: − 2.1(± 4.8) cm; ∆ GLP-1RA: − 2.4(± 4.1) cm. Conclusion: In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.
URI: http://hdl.handle.net/10553/121584
ISSN: 0753-3322
DOI: 10.1016/j.biopha.2023.114561
Fuente: Biomedicine and Pharmacotherapy[ISSN 0753-3322],v. 161:114561 (Mayo 2023)
Colección:Artículos
Adobe PDF (736,27 kB)
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.